<PAGE>   1

                                UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                                        
                              WASHINGTON, DC 20549

                                    FORM 10-Q
                                        
                                        
     [X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
          SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED
          JUNE 30, 1995.
          --------------
                                       OR
     
     [ ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
          SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD 
          FROM _____________ TO ____________.
                                      
                       Commission file number:  0-15006
                                        
                            T CELL SCIENCES, INC.
              (Exact name of registrant as specified in charter)
                                        
            Delaware                          No. 13-3191702
     (State of Incorporation)       (I.R.S Employer Identification No.)
                                        
             115 Fourth Avenue, Needham, Massachusetts 02194-2725
             (Address of principal executive offices)  (Zip code)
                                        
                                (617) 433-0771
             (Registrant's telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that
the registrant was required to file such reports) and (2) has been 
subject to such filing requirements for the past 90 days.  Yes X  No    .
                                                              ----  ----

<TABLE>
<CAPTION>

                                           Class               Outstanding as of
                                           -----                  August 9, 1995
                                                                  --------------
                                 <S>                                  <C>
                                 Common Stock, par value $.001        17,068,507

</TABLE>


                                      1

<PAGE>   2

<TABLE>
                              T CELL SCIENCES, INC.
                                TABLE OF CONTENTS
                                  JUNE 30, 1995
<CAPTION>
                                                                     Page
                                                                     ----
<S>                                                                   <C>

PART I - FINANCIAL INFORMATION
------------------------------
Consolidated Balance Sheets -- June 30, 1995 and
     December 31, 1994..........................................       3

Consolidated Statements of Operations --
     Six months ended June 30, 1995 and 1994....................       4
     Quarters ended June 30, 1995 and 1994......................       5

Consolidated Statements of Cash Flows --
     Six months ended June 30, 1995 and 1994....................       6

Notes to Consolidated Financial Statements......................       7

Management's Discussion and Analysis of Financial Condition            
     and Results of Operations..................................       8


PART II -- OTHER INFORMATION
----------------------------

Item 1.   Legal Proceedings.....................................      12

Item 4.   Submission of Matters to a Vote of
          Security Holders .....................................      12

Item 5.   Other Information.....................................      13

Item 6.   Exhibits and Reports on Form 8-K
     A.   Exhibits..............................................      13
     B.   Reports on Form 8-K...................................      13

Signatures......................................................      15

</TABLE>



     

                                      2

<PAGE>   3

PART I.   FINANCIAL INFORMATION


ITEM 1  FINANCIAL STATEMENTS
       -------------------------

<TABLE>
T CELL SCIENCES
CONSOLIDATED BALANCE SHEET
JUNE 30, 1995 AND DECEMBER 31, 1994
<CAPTION>
                                                                JUNE 30,           December 31,
                                                                  1995                1994
------------------------------------------------------------------------------------------------
                                                                                    (Audited)
<S>                                                           <C>                  <C>
ASSETS                                                                           
                                                                                 
Current Assets:                                                                  
   Cash, Cash Equivalents and Short Term Investments          $ 10,465,083         $ 16,184,319
   Accounts Receivable, Net                                        386,181              551,316
   Inventories                                                     492,854              409,266
   Prepaid Expenses and Other                                      623,867              534,653
------------------------------------------------------------------------------------------------

      Total Current Assets                                      11,967,985           17,679,554
------------------------------------------------------------------------------------------------
                                                                                 
Property and Equipment, Net                                        762,151            1,060,193
Noncurrent Assets                                                2,210,970            1,944,784
------------------------------------------------------------------------------------------------

        Total Assets                                          $ 14,941,106         $ 20,684,531
------------------------------------------------------------------------------------------------
                                                                                 
LIABILITIES AND STOCKHOLDERS' EQUITY                                             
                                                                                 
Current Liabilities:                                                             
   Accounts Payable                                           $  1,074,978         $    786,344
   Accrued Expenses                                                952,486            1,812,508
   Deferred Revenue                                                117,861                    -
------------------------------------------------------------------------------------------------

      Total Current Liabilities                                  2,145,325            2,598,852
------------------------------------------------------------------------------------------------
                                                                                 
Collaborator Advance                                               181,573              500,000
                                                                                 
Stockholders' Equity:                                                            
   Class B preferred stock, $2 Par Value;                                        
      1,163,102 Shares Authorized                                        -                    -
   Class C preferred stock, $.01 Par Value;                                      
      3,000,000 Shares Authorized                                        -                    -
   Common Stock, $.001 Par Value; 50,000,000 Shares                              
      Authorized; 17,056,972 and 17,054,222 Shares                  17,057               17,054
      Issued and Outstanding                                                     
    Additional Paid-in Capital                                  55,712,902           55,726,143
    Less: 8,446 and 16,323 Common Treasury Shares at Cost          (39,830)             (76,931)
    Accumulated Deficit                                        (43,075,921)         (38,080,587)
------------------------------------------------------------------------------------------------
                                                                                 
      Total Stockholders' Equity                                12,614,208           17,585,679
------------------------------------------------------------------------------------------------
        Total Liabilities and Stockholders' Equity            $ 14,941,106         $ 20,684,531
------------------------------------------------------------------------------------------------
</TABLE>

See accompanying notes to financial statements                               
    
                                                           
                                       3

<PAGE>   4

<TABLE>
T CELL SCIENCES
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE SIX MONTHS ENDED JUNE 30, 1995 AND 1994
<CAPTION>
                                                      JUNE 30,            June 30,
                                                        1995                1994
------------------------------------------------------------------------------------
<S>                                                 <C>                 <C>
OPERATING REVENUE:                                                      
                                                                        
Product Development and Licensing Agreements        $ 1,136,616         $ 2,785,000
Product Sales                                         1,237,483           1,725,112
------------------------------------------------------------------------------------
                                                                        
   Total Operating Revenue                            2,374,099           4,510,112
------------------------------------------------------------------------------------
                                                                        
OPERATING EXPENSES:                                                     
                                                                        
Cost of Product Sales                                   972,207           1,037,856
Research and Development                              3,993,600           5,122,779
General and Administrative                            2,047,311           2,441,267
Marketing and Sales                                     737,380             800,626
------------------------------------------------------------------------------------
                                                                        
   Total Operating Expenses                           7,750,498           9,402,528
------------------------------------------------------------------------------------
                                                                        
Operating Loss                                       (5,376,399)         (4,892,416)
                                                                        
Interest Income, Net                                    381,065             676,947
------------------------------------------------------------------------------------
                                                                        
NET LOSS                                            $(4,995,334)        $(4,215,469}
------------------------------------------------------------------------------------
                                                                        
NET LOSS PER COMMON SHARE                           $     (0.29)        $     (0.25)
------------------------------------------------------------------------------------
                                                    
Weighted Average Common Shares Outstanding           17,054,953          17,052,652
------------------------------------------------------------------------------------
</TABLE>

                                                    
See accompanying notes to financial statements

                                        4


<PAGE>   5

<TABLE>
T CELL SCIENCES
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE QUARTERS ENDED JUNE 30, 1995 AND 1994           
<CAPTION>
                                                          JUNE 30,           June 30,
                                                            1995               1994
--------------------------------------------------------------------------------------
<S>                                                     <C>               <C>
OPERATING REVENUE:                                                        
                                                                          
Product Development and Licensing Agreements            $   547,940       $ 1,435,637
Product Sales                                               629,403           808,088
--------------------------------------------------------------------------------------
                                                                          
    Total Operating Revenue                               1,177,343         2,243,725
--------------------------------------------------------------------------------------
                                                                          
OPERATING EXPENSES:                                                       
                                                                          
Cost of Product Sales                                       467,662           552,846
Research and Development                                  2,013,800         2,508,998
General and Administrative                                  987,939         1,312,431
Marketing and Sales                                         444,504           433,396
--------------------------------------------------------------------------------------
                                                                          
    Total Operating Expenses                              3,913,905         4,807,671
--------------------------------------------------------------------------------------
                                                                          
Operating Loss                                           (2,736,562)       (2,563,946)
                                                                          
Interest Income, Net                                        151,689           285,370
--------------------------------------------------------------------------------------
                                                                          
NET LOSS                                                $(2,584,873)      $(2,278,576)
--------------------------------------------------------------------------------------
                                                                          
NET LOSS PER COMMON SHARE                               $     (0.15)      $     (0.13)
--------------------------------------------------------------------------------------
Weighted Average Common Shares Outstanding               17,055,686        17,054,144
--------------------------------------------------------------------------------------
</TABLE>

See accompanying notes to financial statements          
                                                        
                                        5 

<PAGE>   6

<TABLE>
T CELL SCIENCES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 1995 AND 1994
<CAPTION>
                                                                     JUNE 30,            June 30,
                                                                      1995                1994
---------------------------------------------------------------------------------------------------
<S>                                                                <C>                 <C>      
CASH FLOWS FROM OPERATING ACTIVITIES:                                                  
   Net Loss                                                        $(4,995,334)        $(4,215,469)
   Adjustments to Reconcile Net Loss to Net Cash                                       
        Used by Operating Activities:                                                  
             Depreciation and Amortization                             291,026             398,506
                                                                                       
   Net Change in Current Assets and Total Liabilities                 (779,621)           (570,480)
---------------------------------------------------------------------------------------------------

   Net Cash Used by Operating Activities                            (5,483,929)         (4,387,443)
                                                                                       
CASH FLOWS FROM INVESTING ACTIVITIES:                                                  
   Acquisition of Property and Equipment                                (6,945)           (705,253)
   Sale of Equipment, Net                                              106,961         
   Increase in Patents and Other Noncurrent Assets                    (359,186)           (136,542)
   Redemption of Short Term Investments                              8,539,666           2,342,970
   Purchase of Short Term Investments                                        -            (661,828)
---------------------------------------------------------------------------------------------------
                                                                   
   Net Cash Provided by Investing Activities                         8,280,496             839,347
                                                                   
CASH FLOWS FROM FINANCING ACTIVITIES:                               
   Sale of Stock                                                        16,739                   -
   Proceeds from Exercise of Stock Options                               7,124              13,306
---------------------------------------------------------------------------------------------------
                                                                   
Net Cash Provided by Financing Activities                               23,863              13,306
---------------------------------------------------------------------------------------------------

Increase (Decrease) in Cash and Cash Equivalents                     2,820,430          (3,534,790)

Cash and Cash Equivalents at Beginning of Period                     7,644,653           5,151,419
---------------------------------------------------------------------------------------------------

CASH AND CASH EQUIVALENTS AT END OF PERIOD                         $10,465,083         $ 1,616,629
---------------------------------------------------------------------------------------------------
                                                                   
CASH, CASH EQUIVALENTS AND SHORT TERM                              
   INVESTMENTS AT END OF PERIOD                                    $10,465,083         $21,849,014
---------------------------------------------------------------------------------------------------
</TABLE>

See accompanying notes to financial statements

                                                6

<PAGE>   7
                                        
                             T CELL SCIENCES, INC.

                  NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                 JUNE 30, 1995

(1) NATURE OF BUSINESS
    ------------------

     T Cell Sciences, Inc. (the "Company"), was incorporated in the State of
Delaware on December 9, 1983, and is utilizing proprietary complement inhibitor
and T cell receptor technology to develop pharmaceutical products to treat
diseases of inflammation and autoimmunity.  T Cell Diagnostics, Inc. ("TCD"), a
wholly-owned subsidiary of the Company, develops, manufactures and markets
innovative preclinical reagents and immune monitoring products.
     
     The consolidated financial statements include the accounts of T Cell
Sciences, Inc. and its wholly owned subsidiary, T Cell Diagnostics, Inc.  All
intercompany transactions have been eliminated.

(2) INTERIM FINANCIAL STATEMENTS
    ----------------------------

     The accompanying financial statements for the three and six month periods
ended June 30, 1995 and 1994 include the consolidated accounts of the Company,
and have been prepared in accordance with generally accepted accounting
principles for interim reporting information and with the instructions to Form
10-Q and article 10 of Regulation S-X.  In the opinion of management, the
information contained herein reflects all adjustments, consisting solely of
normal recurring adjustments, that are necessary to present fairly the financial
positions at June 30, 1995 and December 31, 1994, the results of operations for
the three and six month periods ended June 30, 1995 and 1994, and the cash flows
for the six month periods ended June 30, 1995 and 1994.  The results of
operations for the three and six month periods ended June 30, 1995 are not
necessarily indicative of results for any future interim period or for the full
year.
     
     Certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles
have been omitted, although the Company believes that the disclosures included
are adequate to make the information presented not misleading.  The consolidated
financial statements and the notes included herein should be read in conjunction
with footnotes contained in the Company's Annual Report on Form 10-K for the
fiscal year ended December 31, 1994.

(3) LITIGATION
    ----------


                                       7

<PAGE>   8

     In December 1994, the Company filed a lawsuit against the landlord of its
former Cambridge, Massachusetts headquarters for damages it has incurred as a
result of the forced evacuation and relocation of its operations due to air
quality problems.  The defendants in this lawsuit have counterclaimed alleging
that the Company has breached its lease obligations.  The Company believes that
losses arising from the counterclaims are not probable and therefore, no amounts
have been recorded in the financial statements.  The Company's insurance carrier
has agreed to reimburse the Company for certain legal expenses associated with
defense of certain of the counterclaims.  In July 1995 the bank holding a
mortgage on the building containing the Company's former facilities filed a
lawsuit against the Company to collect rents it alleges are due to the bank,
instead of the landlord, as a result of an agreement pertaining to the financing
of the initial build-out of the facilities in 1987.  The Company has filed a
motion, which is pending, to dismiss this lawsuit.
     
     The Company brought suit in July 1995 against its insurance carrier, Chubb
& Son, Inc., and the policy underwriter, Federal Insurance Company, for a
judgment that the Company is entitled to insurance coverage for its property and
business interruption losses incurred as a result of the forced evacuation and
relocation.
     
     See Part II., Item 1. --  Legal Proceedings.

(4) SUBSEQUENT EVENTS
    -----------------
 
     In August 1994, the Company entered into a five year agreement which allows
it to lease up to $2,000,000 in machinery, equipment and leasehold improvements.
The lease arrangement requires that the Company maintain certain restrictive
covenants, including maintaining cash, cash equivalents and short term
investment balances of not less than $10,000,000 and certain financial ratios.
During July 1995 the Company's cash balance fell below the minimum covenant
requirement.  As a result, cash collateral will be reserved for amounts
outstanding on the lease until the restrictions are met. At June 30, 1995
$1,568,000 had been drawn against the lease.  The Company intends to continue to
draw against the lease during 1995 to meet its capital requirements.
     


I
TEM 2.   MANAGEMENT'S DISCUSSION AND ANALYSIS OF
        FINANCIAL CONDITION AND RESULTS OF OPERATIONS
        ---------------------------------------------

RESULTS OF  OPERATIONS
     The Company reported a consolidated net loss of $2,584,873 or $.15 per
share for the quarter ended June 30, 1995, compared with a net loss of
$2,278,576 or $.13 per 

                                       8

<PAGE>   9
                  
share for the second quarter ended June 30, 1994.  For  the six months ended
June 30, 1995, the Company reported a consolidated net loss of $4,995,334 or
$.29 per share, compared with a net loss of $4,215,469 or $.25 per share for the
six months ended June 30, 1994.  The increased loss for the quarter ended June
30, 1995 compared to the same period last year was primarily the result of lower
product development revenue and a decline in product sales partially offset by
reduced expenses in all functional areas except marketing and sales which
increased due to expenses associated with the launch of TRAx[Registered] CD4.
     
     Product development revenue decreased 62% or $887,697 to $547,940 for
the quarter ended June 30, 1995 compared to the same quarter last year.  For the
six months ended June 30, 1995 product development revenue decreased 59% to
$1,136,616 compared to $2,785,000 for the same period last year.  The decrease
for the quarter ended June 30, 1995 is primarily the result of anticipated lower
revenue from  the Company's collaborative partner, Astra AB, in accordance with
the Amended and Restated Product Development and Distribution Agreement ("the
Agreement") of December 1993.  Included in product development revenue for the
quarter ended June 30, 1995 is the reduction of an advance from Astra AB for the
construction of laboratory facilities at the Company's former headquarters which
were evacuated during June 1994 due to air quality problems (see part II., item
1.).  The collaborator advance liability has been reduced by $318,427 to
$181,573 based on the Agreement and management's assessment of the Company's
obligations within the agreement.  For the quarter ended June 30, 1994 product
development revenue reflected a milestone payment from Yamanouchi
Pharmaceuticals Co., Ltd. for services performed under the TRAx[Registered]
product marketing agreement.  For the six months ended June 30, 1995 the
decrease in product development is primarily the result of a 46% decrease in
revenue from Astra AB compared to the same period last year, coupled with a
signing fee associated with the former distribution agreement with INCSTAR
Corporation in the first quarter of 1994 and the milestone payment received from
Yamanouchi Pharmaceuticals Co., Ltd. in the second quarter of 1994.
     
     Product sales revenue of $629,403 for the quarter ended June 30, 1995
decreased 22% compared to the same period last year.  For the six months ended
June 30, 1995 product sales revenue decreased 28% to $1,237,483 compared to
$1,725,112 for the comparable period last year.  The decrease in product sales
for the quarter and six months ended June 30, 1995 is primarily attributable to
increased competition with resulting price and volume erosion on certain
products and continued weakness in the international diagnostic product market.
In May 1995 the Company received clearance from the U.S. Food and Drug
Administration to market the TRAx[Registered] CD4 

                                       9

<PAGE>   10
test kit.  The TRAx[Registered] CD4 test kit is an in vitro diagnostic test kit
which provides a method for enumerating CD4 T cells, a type of white blood cell
monitored by physicians treating patients infected with HIV.  The Company
launched the TRAx[Registered] CD4 test kit in the U.S. during the second quarter
through a direct sales effort with the first customer shipment in July 1995.
     
     Gross margins decreased to 25.7%  for the quarter ended June 30, 1995
compared to 31.6% for the quarter ended June 30, 1994.  For the six months ended
June 30, 1995 gross margin was 21.4% compared to 39.8% for the same period last
year.  The decrease for the quarter and six months is primarily due to
inefficiencies of producing at lower volumes.
     
     Research and development expenses decreased $495,198 or 20% for the
quarter ended June 30, 1995 compared to the same period last year.  The decrease
is primarily attributable to the Company's cost containment programs implemented
during the latter part of 1994, partially offset by costs associated with two
phase I clinical trials evaluating the use of  TP10, (soluble complement
receptor type 1).  The first phase I clinical trial began in the latter part of
1994 in patients at risk of developing adult respiratory distress syndrome.  A
second phase I clinical trial to evaluate the use of TP10 in reperfusion injury
following heart attack was initiated during the second quarter of 1995.  For the
six months ended June 30, 1995  research and development expenses were
$3,993,600 compared to $5,122,779 for the same period last year.  The decrease
is primarily attributable to the Company's cost containment program combined
with additional costs incurred in the first quarter of 1994 relating to the
supplemental clinical trial conducted for TRAx[Registered] CD4, partially offset
by costs associated with the phase I clinical trials evaluating the use of TP10.
     
     General and administrative expenses decreased to $987,939 and $2,047,311
for the quarter and six months ended June 30, 1995, respectively, from
$1,312,431 and $2,441,267 for the comparable period last year.  Reorganization
of responsibilities and discretionary cost containment programs implemented
during 1994 and continued in 1995  have contributed to the decrease in expense
in these administrative areas.
     
     The operating loss increased 7% to $2,736,562 for the quarter ended June
30, 1995 from $2,563,948 for the quarter ended June 30, 1994.  For the six
months ended June 30, 1995 the operating loss was $5,376,399, a 10% increase
compared to $4,892,418 for the prior year.  In July 1995, the Company
implemented a restructuring program across all functional areas to reduce
expenses and cash consumption and to improve  

                                      10

<PAGE>   11
manufacturing and associated skills and capabilities.  The Company expects
the restructuring program to significantly reduce expenses and result in
restructuring related expenses in the third quarter of 1995 of approximately
$250,000.
     
     Interest income decreased 47% to $151,689 for the quarter ended June 30,
1995 compared with $285,370 for the quarter ended June 30, 1994.  For the six
months ended June 30, 1995 interest income was $381,065 compared to $676,947 in
the prior year.  The decrease is the result of lower cash balances during the
quarter and six month period ended June 30, 1994 compared to the same periods
last year.
     
LIQUIDITY AND CAPITAL RESOURCES
     The Company had cash, cash equivalents and short term investments of
approximately $10,465,000 at June 30, 1995.  The balance decreased
$5,719,000 from $16,184,000 at December 31, 1994 and $11,384,000 from
$21,849,000 at June 30, 1994.  The decrease from December 31, 1994 is primarily
due to the net operating loss of $4,995,000 for the six months ended June 30,
1995.  The decrease from June 30, 1994 is primarily due to the net operating
loss for the twelve month period ended June 30, 1995 which included property and
business interruption losses associated with the air quality problems and
subsequent forced evacuation of the Company's former headquarters during the
latter half of 1994.  The Company has filed suit against its insurance carrier
and the policy underwriter for a coverage decision on these losses (see part
II., item 1.).  Also included were realized losses from maturities and other
sales of securities incurred in the second half of 1994.
     
     The Company has no long-term debt.  During 1994, the Company entered into
an operating lease agreement with a five year term to lease up to $2 million of
equipment.  The lease arrangement requires that the Company maintain certain
restrictive covenants, including maintaining cash, cash equivalents and short
term investment balances of not less than $10,000,000 and certain financial
ratios.  During July 1995 the Company's cash balance fell below the minimum
covenant requirement.  As a result, cash collateral will be reserved for amounts
outstanding on the lease until the restrictions are met.  At June 30, 1995
$1,568,000 had been drawn against the lease.  The Company intends to continue to
draw against the lease during 1995 to meet its capital requirements.
     
     The Company believes its current cash, cash equivalents and short term
investments combined with anticipated net cash provided by operations will be
adequate to meet the Company's cash requirements for operations into 1996 and
the Company is considering additional sources of funding through collaborative
arrangements, capital financing and other 

                                      11

<PAGE>   12
avenues to meet cash requirements through 1996 and into the future.




P
ART II.  OTHER INFORMATION


ITEM 1.  LEGAL PROCEEDINGS:
         ------------------

     In connection with the Company's air quality  problems which caused skin
and respiratory irritations to a large number of its employees, the Company is
now a party to several lawsuits.  As discussed in the Company's Annual Report on
Form 10-K, the Company filed a lawsuit in December 1994 against the landlord of
its former Cambridge, Massachusetts headquarters for damages it has incurred as
a result of the forced evacuation and relocation of its operations.  The
defendants in this lawsuit have counterclaimed alleging that the Company has
breached its lease obligations.  This lawsuit is in the discovery stages and the
Company continues to believe that it will be successful in its claims and
defenses.  In July 1995 the bank holding a mortgage on the building in which the
Company's former facilities were located filed a lawsuit against the Company to
collect rents it alleges are due to the bank, instead of the landlord, as a
result of an agreement pertaining to the financing of the initial build-out of
the former facilities in 1987.  The Company has filed a motion, which is
pending, to dismiss this lawsuit.
     
     As reported in the Company's Annual Report of Form 10-K, the Company filed
a claim with its insurance carrier, Chubb & Son, Inc. ("Chubb"), for property
and business interruption losses it has incurred as a result of the air quality
problem and evacuation and relocation of all of its operations.  Despite
repeated attempts by the Company to obtain an  insurance recovery for its
covered losses, Chubb has failed to either cover any of the losses or formally
deny the claims.  As a result, the Company brought suit in July 1995 against
Chubb and the policy underwriter, Federal Insurance Company, which claims that
the Company is entitled to insurance coverage and that the defendants have
engaged in unfair and deceptive practices and which seeks judgment for its
losses and treble damages.  This lawsuit is in the preliminary stages.
     
     

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
         ---------------------------------------------------

     On May 18, 1995 the Company held its Annual Meeting of Stockholders at
which the voters elected six directors to its Board of Directors.  Although his
name had been submitted for nomination as Director, Mr. Ronald M. Urvater
retired from the Board of Directors effective May 1995.


                                      12

<PAGE>   13

<TABLE>
     At the Company's Annual Meeting of Stockholders, the following were elected
to the Board of Directors:
<CAPTION>
                                            For    Withhold Authority
                                            ---    ------------------
          <S>                           <C>            <C>
          James D. Grant                11,486,323     192,871
          Patrick C. Kung               11,484,923     194,271
          Alan W. Tuck                  11,484,423     194,771
          John P. Munson                11,486,213     192,981
          John Simon                    11,484,923     194,271
          Thomas R. Ostermueller        11,481,823     197,371
</TABLE>

     
     The number of shares issued, outstanding and eligible to vote as of the
record date of March 24, 1995 were 17,037,899.  Quorum was 11,679,194 shares
represented by 307 proxies or 68.5% of the eligible voting shares tabulated.
     


ITEM 5.  OTHER INFORMATION:
         ------------------

     On June 7, 1995 the Company announced the formation of Global Pharma Ltd.,
a Bermuda company, whose purpose is to expand and extend the uses and markets
for Chinese government approved ethical pharmaceuticals within China and to
select and acquire unrecognized Chinese pharmaceuticals for development in other
markets of the world.  Patrick Kung, Ph.D., T Cell Sciences' scientific founder
and Vice Chairman is President and Chairman of Global Pharma.  Global Pharma
completed its first round of financing in September 1994 with several private
investors and established a joint venture in China which began operations in
February 1995.  The Company now owns a minority position in Global Pharma.
     
     On July 6, 1995 the Company announced the completion of patient accrual in
its phase I clinical trial evaluating the use of TP10, the product name for
soluble complement receptor 1, in adult respiratory distress syndrome ("ARDS").
Trial results will be summarized during the American Association of Chest
Physicians Meeting in late October 1995.
     
     

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K
         --------------------------------

A. EXHIBITS
     10.9 Master Equipment Lease Agreement        page 16
          Fleet Credit Corporation, Lessor

B. REPORTS ON FORM 8-K
     
     During the second quarter of 1995 the Company filed a Form 8-K, dated
May 18, 1995, reporting that it's subsidiary, T Cell Diagnostics, Inc., received
clearance from the U.S. Food and Drug Administration to market  the
TRAx[Registered] CD4 test kit.  The TRAx[Registered] CD4 test kit is an in vitro


                                      13

<PAGE>   14

diagnostic test kit which provides a method for enumerating CD4 T cells, a type
of white blood cell monitored by physicians treating patients infected with HIV.
     
                                      14


<PAGE>   15


                                   SIGNATURES
                                        
     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                                T CELL SCIENCES, INC.
                                                                                
                                                 BY:  /s/Alan W. Tuck
                                                     -----------------
                                                     President & Chief
                                                     Executive Officer


                                                                                
                                      15





<PAGE>   1

<TABLE>
<S>                                                             <C>
[LOGO]                                                          Master Equipment Lease Agreement
FLEET Credit Corporation                                        No. 31816-
                                                                    -----------

LESSOR:    FLEET CREDIT CORPORATION                             LESSEE:   T Cell Sciences, Inc.
                                                                --------------------------------------------
           a Rhode Island Corporation ("Lessor")                          a Delaware Corporation ("Lessee")
ADDRESS:   111 Westminster Street                               --------------------------------------------
           Providence, Rhode Island 02903                       ADDRESS:  38 Sidney Street
           Telephone (401) 278-6911                             --------------------------------------------
                                                                          Cambridge, Massachusetts 02139
                                                                --------------------------------------------

                                                                --------------------------------------------
</TABLE>


1. LEASE OF EQUIPMENT

        By this Master Equipment Lease Agreement which, together with all Lease
Schedules, Acceptance Certificates, riders, exhibits, amendments and other 
documents now or hereafter attached hereto and made a part hereof, is 
hereinafter referred to as the "Lease", Lessor leases to Lessee and Lessee
leases from Lessor, subject to terms and conditions contained in this Lease,
the personal property, together with all replacement parts, repairs, additions
and accessories (collectively, the "Equipment") described in any Lease Schedule
which shall become a part hereof.  Notwithstanding anything to the contrary 
expressed or implied in this Lease, the terms and conditions of this Lease 
shall be construed and interpreted as to each Lease Schedule as if a
separate but identical lease shall have been executed between the parties
with
 regard to the Equipment on such Lease Schedule. The Equipment is to be
delivered and installed at Lessee's expense at the location specified on the
applicable Lease Schedule. The Equipment shall be deemed to have been accepted  
by Lessee for all purposes under this Lease upon Lessor's receipt of an 
Acceptance Certificate with respect to such Equipment, executed by Lessee 
after receipt of all other documentation required by Lessor with respect to
such Equipment. Lessor shall not be liable or responsible for any failure or
delay in the delivery of the Equipment to Lessee for whatever reason.

2. TERM AND RENT                          

        The term of this Lease shall commence on the date hereof and the lease
term of each item of Equipment shall commence on the date of the Acceptance
Certificate with respect to such item and shall continue for the number of
months, and any proration thereof, specified in the applicable Lease Schedule.
Rental payments shall be in the amounts and shall be due and payable as set
forth in the applicable Lease Schedule. Lessee shall, in addition, pay interim
rent to Lessor on a pro-rata basis from the Acceptance Date to the Lease Term
Commencement Date set forth in the applicable Acceptance Certificate on such
Lease Term Commencement Date. If any rent or other amount payable hereunder
shall not be paid with in 10 days of the date when due, Lessee shall pay as an
administrative and late charge an amount equal to 5% of the amount of any such
overdue payment. In addition, Lessee shall pay interest on such delinquent
payment from 30 days after the due date until paid at the rate of 1 1/2% per
month or the maximum amount permitted by law, whichever is lower. All payments
to be made to Lessor shall be made to Lessor at the address shown above, or at
such other place as Lessor shall specify in writing.  EXCEPT AS OTHERWISE 
EXPRESSLY SET FORTH IN WRITING EXECUTED BY LESSOR AND LESSEE, THIS IS A 
NON-CANCELABLE, NON-TERMINABLE LEASE FOR THE TERM SET FORTH IN EACH LEASE 
SCHEDULE HERETO.

3. POSSESSION; PERSONAL PROPERTY

        No right, title or interest in the Equipment shall pass to Lessee other
than the right to maintain possession and use of the Equipment for the full
lease term (provided no Event or Default has occurred) free from interference
by any person claiming by, through, or under Lessor. The Equipment shall always
remain personal property even though the Equipment may hereafter become
attached or affixed to real property. Lessee agrees to give and record such
notices and to take such other action at its own expense as may be necessary to
prevent any third party (other than an assignee of Lessor) from acquiring or
having the right under any circumstances to acquire any interest in the
Equipment or this Lease. In the event such third party does acquire or have the
right to acquire any interest in the Equipment or this Lease, Lessee shall
remove such third party's interest within 30 days of its being asserted.

4. DISCLAIMER OF WARRANTIES

        LESSOR IS NOT THE MANUFACTURER OR SUPPLIER OF THE EQUIPMENT, NOR THE
AGENT THEREOF, AND MAKES NO EXPRESS OR IMPLIED WARRANTIES AS TO ANY MATTER 
WHATSOEVER, INCLUDING, WITHOUT LIMITATION, THE MERCHANTABILITY OF THE 
EQUIPMENT, ITS FITNESS FOR A PARTICULAR PURPOSE, ITS DESIGN OR CONDITION, ITS
CAPACITY OR DURABILITY, THE QUALITY OF THE MATERIAL OR WORKMANSHIP OR
CONFORMITY OF THE EQUIPMENT TO THE PROVISIONS AND SPECIFICATIONS OF ANY 
PURCHASE ORDER RELATING THERETO, OR PATENT INFRINGEMENTS, AND HEREBY DISCLAIMS
ANY SUCH WARRANTY. LESSOR IS NOT RESPONSIBLE FOR ANY REPAIRS OR SERVICE TO THE
EQUIPMENT, DEFECTS THEREIN OR FAILURES IN THE OPERATION THEREOF. Lessee has
made the selection of each item of Equipment and the manufacturer and/or
supplier thereof based on its own judgment and expressly disclaims any reliance
upon any statements or representations made by Lessor. For so long as no Event
of Default has occurred and is continuing, Lessee shall be the beneficiary of,
and shall be entitled to, all rights under any applicable manufacturer's or
vendor's warranties with respect to the Equipment, to the extent permitted by
law.
        If the Equipment is not delivered, is not properly installed, does not
operate as warranted, becomes obsolete, or is unsatisfactory for any reason
whatsoever, Lessee shall make all claims on account thereof solely against the
manufacturer or supplier and not against Lessor, and Lessee shall nevertheless
pay all rentals and other sums payable hereunder. Lessee acknowledges that
neither the manufacturer or supplier of the Equipment, nor any sales
representative or agent thereof, is an agent of Lessor, and no agreement or
representation as to the Equipment or any other matter by any such sales
representative or agent of the manufacturer or supplier shall in any way affect
Lessee's obligations hereunder.

--------------------------------------------------------------------------------
        This Lease consists of nineteen sections, including the terms and
provisions contained on the reverse side hereof, and the terms and provisions
of any Lease Schedule, Acceptance Certificate, rider, exhibit, amendment or
other document now or hereafter attached hereto and made a part hereof. THIS
LEASE REPRESENTS THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE
CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS OR SUBSEQUENT ORAL 
AGREEMENTS BETWEEN THE PARTIES.  LESSEE ACKNOWLEDGES AND CERTIFIES THAT 
NO SUCH ORAL AGREEMENTS EXIST. This Lease may not be amended, nor may any
rights hereunder be waived, except by an instrument in writing signed by the
party charged with such amendment or waiver. The term "Lessee" as used herein
shall mean and include any and all Lessees who sign hereunder, each of whom
shall be jointly and severally bound hereby. This Lease will not be binding on
Lessor until executed by Lessor.






                                     By execution hereof, the signed certifies
                                     that he or she has read, accepted and
                                     duly executed this Master Equipment Lease
DATED AS OF: August 5, 1994          Agreement on behalf of Lessee.
             ---------   --

LESSOR: FLEET CREDIT CORPORATION     LESSEE: T Cell Sciences 

By: /s/ Lina M. Ferruolo             By: /s/ Alan W. Tuck          
    ----------------------------         -------------------------------

Title:  AVP                          Title: President and CEO   
       --------------------------           --------------------------


<PAGE>   2
5. REPRESENTATIONS, WARRANTIES AND COVENANTS

        Lessee represents and warrants to and covenants with Lessor that:

        (a) Lessee has the form of business organization indicated above and is
duly organized and existing in good standing under the laws of the state listed
in the caption of the Lease and is duly qualified to do business wherever
necessary to carry on its present business and operations and to own its
property; (b) this Lease has been duly authorized by all necessary action on
the part of Lessee consistent with its form of organization, does not require
any further shareholder or partner approval, does not require the approval of,
or the giving notice to, any federal, state, local or foreign governmental
authority and does not contravene any law binding on Lessee or contravene any
certificate or articles of incorporation or by-laws or partnership certificate
or agreement, or any agreement, indenture, or other instrument to which Lessee
is a party or by which it may be bound; (c) this Lease has been duly executed
and delivered by authorized officers or partners of Lessee and constitutes a
legal, valid and binding obligation of Lessee enforceable in accordance with
its terms; (d) Lessee has not and will not, directly or indirectly, create,
incur or permit to exist any lien, encumbrance, mortgage, pledge, attachment or
security interest on or with respect to the Equipment or this Lease (except
those of persons claiming by, th rough or under Lessor); (e) the Equipment will
be used solely in the conduct of Lessee's business and will remain in the
location shown on the applicable Lease Schedule unless Lessor and Lessee
otherwise agree in writing and Lessee has completed all notifications, filings,
recordings, and other actions in such new location as Lessor may reasonably
request to protect Lessor's interest in the Equipment; (f) there are no pending
or threatened actions or proceedings before any court or administrative agency
which materially adversely affect Lessee's financial condition or operations
and all credit, financial and other information provided by Lessee or at
Lessee's direction is, and all such information hereafter furnished will be,
true and correct in all material respects; and (g) Lessor has not selected,
manufactured or supplied the Equipment to Lessee and has acquired any Equipment
subject hereto solely in connection with this Lease and Lessee has received and
approved the terms of any purchase order or agreement with respect to the
Equipment.

6. INDEMNITY

        Lessee assumes the risk of liability for, and hereby agrees to
indemnify and hold safe and harmless, and covenants to defend, Lessor, its
employees, servants and agents from and against; (a) any and all liabilities,
losses, damages, claims and expenses (including legal expenses of every kind
and nature) arising out of the manufacturing, purchase, shipment and delivery
to Lessee, acceptance or rejection, ownership. titling, registration, leasing,
possession, operations, use, return or other disposition of the Equipment,
including, without limitation, any of such as may arise from patent or latent
defects in the Equipment (whether or not discoverable by Lessee), any claims
based on absolute tort liability or warranty and any claims based on patent,
trademark or copyright infringement; (b) any and all loss or damage of or to
the Equipment, normal wear and tear excepted; and (c) any obligation or
liability to the manufacturer and any supplier of the Equipment arising under
the purchase orders issued by or assigned to Lessor.

        The covenants and indemnities contained in this Section and Section 7
shall survive the termination of this Lease.

7. TAXES AND OTHER CHARGES

        Lessee agrees to comply with all laws, regulations and governmental
orders related to this Lease and to the Equipment and its use or possession,
and to pay when due and to defend and indemnify Lessor against liability for
all license fees, assessments, and sales, use, property, excise, privilege and
other taxes (including any related interest or penalties) or other charges or
fees now or hereafter imposed by any governmental body or agency upon any
Equipment, or with respect to the manufacturing, ordering, shipment, purchase,
ownership, delivery, installation, leasing, operation, possession, use, return,
or other disposition thereof or the rentals hereunder (other than taxes on or
measured solely by the net income of Lessor). Any fees, taxes or other lawful
charges paid by Lessor upon failure of Lessee to make such payments shall at
Lessor's option become immediately due from Lessee to Lessor.

        If a Lease Schedule denominated as a True Lease Schedule shall be made
a part of this Lease, then, with respect to the Equipment set forth on such
True Lease Schedule, Lessor has assumed the following tax benefits (the "Tax
Benefits"): (i) that it will be entitled to cost recovery deductions under
Section 168 of the Internal Revenue Code of 1986, as amended (the "Code"),
using a 200% declining balance method of depreciation switching to the
straight-line method for the first taxable year for which such method will
yield larger depreciation deductions, and assuming a half-year convention and
zero salvage value, for the applicable recovery period for such Equipment as
set forth in the True Lease Schedule with respect to the Equipment, and (ii)
that Lessor will be taxed throughout the term of the Lease Schedule at Lessors
federal corporate income tax rate existing on the date of such Lease Schedule
(the "Assumed Tax Rate"). If, for any reason whatsoever, there shall be a loss,
disallowance, recapture or delay in claiming all or any portion of the Tax
Benefits with respect to any of the Equipment, or there shall be included in
Lessors gross income for Federal, state or local income tax purposes any amount
on account of any addition, modification or improvement to or in respect of any
of the Equipment made or paid for by Lessee, or if there shall be a change in
the Assumed Tax Rate (any loss, disallowance, recapture, delay, inclusion or
change being herein call a "Tax Loss"), then thirty (30) days after written
notice to Lessee by Lessor that a Tax Loss has occurred, Lessee shall pay
Lessor a lump sum amount which, after deduction of all taxes required to be
paid by Lessor with respect to the receipt of such amount, will provide Lessor
with an amount necessary to maintain Lessor's after-tax economic yield and
overall net after-tax cash flows at at least the same level that would have
been available if such Tax Loss has not occurred, plus any interest, penalties
or additions to tax which may be imposed in connection with such Tax Loss. In
lieu of paying such Tax Loss in a lump sum, Lessor may require, or upon
Lessee's request, may agree, in Lessors sole discretion, that such Tax Loss be
paid in equal periodic payments over the applicable remaining Lease term with
respect to such Equipment with each such payment due and payable at the time
each rental payment is due and payable with respect to such Equipment. A Tax
Loss shall conclusively be deemed to have occurred if either (a) deficiency
shall have been proposed by the Internal Revenue Service or other taxing
authority having jurisdiction, or (b) tax counsel for Lessor has rendered an
opinion to Lessor that such Tax Loss has so occurred. The foregoing indemnity
shall continue in full force and effect notwithstanding the expiration or
termination of the Lease or the Lease Term of the Schedule Equipment and each
item thereof.

8. DEFAULT 
 
        Lessee shall be in default of this Lease upon the occurrence of any one
or more of the following events (each an "Event of Default"):

        (a) Lessee shall fail to make any payment, or rent or otherwise,
hereunder within 10 days of the date when due; or (b) Lessee shall fail to
obtain or maintain any of the insurance required herein; or (c) Lessee shall
fail to perform or observe any covenant, condition or agreement under this
Lease, and such failure continued for 10 days after notice thereof to Lessee;
or (d) Lessee shall default in the payment or performance of any indebtedness
or obligation to Lessor or any parent, subsidiary or affiliated company of
Lessor under any note, security agreement, equipment lease, title retention or
conditional sales agreement or any instrument or agreement evidencing such
indebtedness with Lessor or any parent, subsidiary or affiliated company of
Lessor; or (e) any representation or warranty made by Lessee heroin or in any
certificate, agreement, statement or document heretofore or hereafter furnished
Lessor in connection herewith including, without limitation, any financial
information disclosed to Lessor, shall prove to be false or incorrect in any
material respect; or (f) death or judicial declaration of incompetence of
Lessee, if an individual; the commencement of any bankruptcy, insolvency,
arrangement, reorganization, receivership, liquidation or other similar
proceeding by or against Lessee or any of its properties or business, or the
appointment of a trustee, receiver, liquidator or custodian for Lessee or any
of its properties of business, or if Lessee suffers the entry of an order for
relief under Title 11 of the United States Code; or the making by Lessee of a
general assignment or deed of trust for the benefit of creditors; or (g) Lessee
shall default in any payment or other obligation to any third party and any
applicable grace or cure period with respect thereto has expired; or (h) Lessee
shall terminate its existence by merger, consolidation, sale of substantially
all of its assets or otherwise; or (i) if Lessee is a privately held
corporation, more than 50% of Lessee's voting capital stock, or effective
control of Lessee's voting capital stock, issued and outstanding from time to
time, is not retained by the holders of such stock on the date of this Lease;
or (j) if Lessee is a publicly held corporation, there shall be a change in the
ownership of Lessee's stock such that Lessee is no longer subject to the
reporting requirements of the Securities Act of 1934 or no longer has a class
of equity securities registered under Section 12 of the Securities Act of 1934;
or (k) Lessor shall determine, in its sole discretion and in good faith, the
there has been a material adverse change in the financial condition of the
Lessee since the date of this Lease or that Lessee's ability to make any
payment hereunder promptly when due or otherwise comply with the terms of this
Lease or any other agreement between Lessor and Lessee is impaired; or (l) any
event or condition set forth in subsections (b), (c), (d), (e), (f), (g), (h),
(i), (j), or (k) of this Section 8 shall occur with respect to any guarantor or
other person responsible, in whole or in part, for payment or performance of
this Lease; or (m) any event or condition set forth in subsections (d), (e),
(f), (g), (h), (i) or (j) shall occur with respect to any owner or parent,
affiliate or subsidiary corporation of Lessee.

        Lessee shall promptly notify Lessor of the occurrence of any Event of
Default or the occurrence or existence of any event or condition which, upon
the



<PAGE>   3
giving of notice or lapse of time, or both, may become an Event of Default.

9. REMEDIES

        Upon the occurrence of any Event of Default, Lessor may, at its sole
option and discretion, exercise one or more of the following remedies with
respect to any or all of the Equipment: (a) cause Lessee to promptly return,
upon written demand and at Lessee's sole expense, any or all Equipment to such
location as Lessor may designate in accordance with the terms of Section 18, or
Lessor, at its option, may enter upon the premises where the Equipment is
located and take immediate possession of and remove the same by summary
proceedings or otherwise, all without liability to Lessor for or by reason of
damage to property or such entry or taking possession except for Lessor's gross
negligence or willful misconduct; (b) sell any or all the Equipment at public
or private sale or otherwise dispose of, hold, use, operate, lease to others or
keep idle the Equipment, all as Lessor in its sole discretion may determine and
all free and clear of any rights of Lessee; (c) remedy such default, including
making repairs or modifications to the Equipment, for the account of and the
expense of Lessee and Lessee agrees to reimburse Lessor for all of Lessor's
costs and expenses; (d) by written notice to Lessee, terminate this Lease with
respect to any or all Lease Schedules in default and the Equipment subject
thereto, as such notice shall specify, and, with respect to such terminated
Lease Schedules and Equipment, declare immediately due and payable and recover
from Lessee, as liquidated damages for loss of a bargain and not as a penalty,
an amount equal to the sum of (i) all rental payments accrued and unpaid, plus
interest and late charges thereon, calculated as of the date payment is
actually made, plus (ii) the applicable Stipulated Loss Value with respect
thereto (hereinafter defined), plus (iii) all other amounts then payable to
Lessor hereunder; (e) apply any deposit or other cash collateral or sale or
remarketing proceeds of the Equipment at any time as it sees fit to reduce any
amounts due to Lessor, and (f) exercise any other right or remedy which may be
available to it under applicable law, or proceed by appropriate court action to
enforce the terms hereof or to recover damages for the breach hereof, including
reasonable attorneys' fees and court costs.

        No remedy referred to in this Section 9 is intended to be exclusive,
but each shall be cumulative and in addition to any other remedy referred to
above or otherwise available to Lessor at law or in equity. The exercise or
beginning of exercise by Lessor of any one or more of such remedies shall not
preclude the simultaneous or later exercise by Lessor of any or all such other
remedies and all remedies hereunder shall survive termination of this Lease.

        At any sale of the Equipment pursuant to this Section 9, Lessor may bid
for and purchase the Equipment. Notice required, if any, of any sale or other
disposition hereunder by Lessor shall be satisfied by the mailing of such
notice to Lessee at least seven (7) days prior to the sale or other 
disposition. In the event Lessor takes possession and disposes of the 
Equipment, Lessor shall give Lessee credit for any sums actually received by
Lessor from the disposition of the Equipment after deductions of expenses of
disposition and the amounts due to Lessor under Section 9 (d) above. A
termination shall occur only upon written notice by Lessor and only with
respect to such Equipment as Lessor shall specify by such notice. Termination
under this Section 9 shall not affect Lessee's duty to perform Lessee's
obligations hereunder to Lessor in full. Lessee agrees to reimburse Lessor on
demand for any and all costs and expenses incurred by Lessor in enforcing its
rights and remedies hereunder following the occurrence of an Event of Default,
including, without limitation, reasonable attorneys' fees, and the costs of
repossession, storage, insuring, reletting, selling and disposing of any and
all Equipment.

        The term "Stipulated Loss Value" as used in this Lease shall mean the
Stipulated Loss Value calculated and as set forth in any Schedule of Stipulated
Loss Values attached to and made a part of any Lease Schedule hereto with
respect to the Equipment set forth in such Lease Schedule. If there is no such
Schedule of Stipulated Loss Values applicable to such Lease Schedule and
Equipment, then the Stipulated Loss Value shall mean, for any particular date,
the net present value of all rental payments then remaining unpaid for the term
of the Lease Schedule plus the amount of any purchase or renewal option or
obligation with respect to the Equipment or, if there is no such option or
obligation, then the fair market value of the Equipment at the end of such
term, as estimated by Lessor in its sole, reasonable discretion, discounted at
a rate of the 1-year Treasury Constant Maturity rate as published in the
Selected Interest Rates Table of the Federal Reserve statistical release H.15
(519) for the Week Ending immediately prior to the original Acceptance Date for
such Equipment as set forth in the Acceptance Certificate applicable thereto.

10. ADDITIONAL SECURITY

        Lessee hereby grants to Lessor a security interest in all personal
property, whether now owned by Lessee or hereafter acquired by purchase from
Lessor, now or hereafter leased to Lessee by Lessor or financed by Lessor under
any lease, security, loan or conditional sales agreement or any other document
or instrument. Such security interest is granted to secure the prompt payment
and performance when due (by reason of acceleration or otherwise) of each and
every indebtedness, obligation or liability, whether now existing or
hereinafter incurred of Lessee, or any affiliate, parent or subsidiary of
Lessee, to Lessor, including but not limited to the liabilities of Lessee under
this Lease. The extent to which Lessor shall have a purchase money security
interest in any item of Equipment that is subject to a Lease Schedule which is
deemed to create a security interest under Section 1-201 (37) of the Uniform
Commercial Code shall be determined by reference to the Acquisition Cost of
such item financed by Lessor. In order more fully to secure its rental payments
and all other obligations to Lessor hereunder, Lessee hereby grants to Lessor a
security interest in any deposit of Lessee to Lessor under Section 3 (d) of any
Lease Schedule hereto. Such security deposit shall not bear interest, may be
commingled with other funds of Lessor and shall be immediately restored by
Lessee if applied under Section 9 (e). Upon expiration of the term of this
Lease and satisfaction of all of Lessee's obligations, the security deposit
shall be returned to Lessee. The term "Lessor" as used in this Section 10 shall
include any subsidiary, parent or affiliate of Lessor.

11. NOTICES

        Any notices and demands required or permitted to be given under this
Lease shall be given in writing and by regular mail and shall become effective
when deposited in the United States mail with postage prepaid to Lessor to the
attention of Customer Accounts, and to Lessee at the addresses herein above set
forth, or to such other address as the party to receive notice hereafter
designates by such written notice.

12. MAINTENANCE; INSPECTIONS; LOSS AND DAMAGE

        During the term of the Lease for each item of Equipment, the Lessee
shall, unless the Lessor shall otherwise consent in writing; (a) permit each
item to be used only with in the continental United States by qualified
personnel solely for business purposes and the purpose for which it was
designed and, at its sole expense, service, repair, overhaul and maintain each
item in the same condition as when received, ordinary wear and tear excepted,
in good operating order, consistent with prudent industry practice (but, in no
event less than the same extent to which Lessee maintains, in the prudent
management of its equipment, other similar properties of Lessee) and in
compliance with all applicable laws, ordinances, regulations, and conditions of
all insurance policies required to be maintained by Lessee under the Lease and
all manuals, orders, recommendations, instructions and other written
requirements as to the repair and maintenance of such item issued at any time
by the vendor and/or manufacturer thereof; (b) maintain conspicuously on each
item such labels, plates, decals or other markings as Lessor may reasonably
require, stating that Lessor is owner of such item; (c) make no additions,
alterations, modifications or improvements (collectively, "Improvements") to
any item that are not readily removable without causing material damage to such
item or which will cause the value, utility or useful life of such item to
materially decline. If any such Improvement is made and cannot be removed
without causing material damage or decline in value, utility or useful life (a
"Non-Severable Improvement"), then Lessee warrants that such Non-Severable
Improvement shall immediately become the Lessor's property upon being installed
and shall be free and clear of all liens and encumbrances and shall become
Equipment subject to all of the terms and conditions of the Lease. All such
Improvements that are not Non-Severable Improvements shall be removed by Lessee
prior to the return of the item hereunder or such Improvements shall also
become the sole and absolute property of Lessor without any further payment by
Lessor to Lessee and shall be free and clear of all liens and encumbrances
whatsoever.  Lessee shall repair all damage to any item caused by the removal of
any Improvement so as to restore such item to the same condition which existed
prior to its installation and as required by this Lease.

        During the term of the Lease and any extensions and renewals thereof,
and during any storage period as set forth below, the Lessee shall furnish to
Lessor such information concerning the condition, location, use and operation
of the Equipment as Lessor may reasonably request and shall permit any person
designated by Lessor to visit and inspect any item of Equipment and any records
maintained in connection therewith. If any item of Equipment does not comply
with the requirements of this Lease, Lessee shall, within 30 days of written
notice from Lessor, bring such Equipment into compliance; provided, however,
that the failure of Lessor to inspect the Equipment or to inform Lessee of any
noncompliance shall not relieve Lessee of any of its obligations hereunder. 

        Lessee hereby assumes all risk of loss, damage or destruction for
whatever reason to the Equipment from and after the earlier of the date (a) on
which the Equipment is ordered, or (b) Lessor pays the purchase price of the
Equipment, and continuing until the Equipment has been returned to, and
accepted by Lessor in the condition required by Section 18 hereof.  If any item
of Equipment shall become lost, stolen, destroyed, damaged beyond repair or



<PAGE>   4
rendered permanently unfit for use for any reason, or in the event of any
condemnation, confiscation, theft or seizure or requisition of title to or use
of such item, Lessee shall promptly pay to Lessor an amount equal to the
Stipulated Loss Value of such item.

13. INSURANCE

        Lessee shall procure and maintain insurance in such amounts and upon
such terms and with such companies as Lessor may approve during the entire term
of this Lease and until the Equipment has been returned to, and accepted by,
Lessor in the condition required by Section 18 hereof, at Lessee's expense,
provided that in no event shall such insurance be less than the following: (a)
Worker's Compensation and Employer's Liability Insurance, in the full statutory
amounts provided by law; (b) Comprehensive General Liability Insurance
including product/completed operations and contractual liability Coverage, with
minimum limits of the greater of (i) $1,000,000 each occurrence, and Combined
Single Limit Body Injury and Property Damage, $1,000,000 aggregate, where
applicable, or (ii) as otherwise specified in any Lease Schedule hereto; and
(c) All Risk Physical Damage Insurance, including earthquake and flood, on each
item of Equipment, in an amount not less than the Stipulated Loss Value of the
Equipment. Lessor will be included as an additional insured and loss payee as
its interest may appear. Such policies shall be endorsed to provide that the
coverage afforded to Lessor shall not be rescinded, impaired or invalidated by
any act or neglect of Lessee. Lessee agrees to waive Lessee's right and its
insurance carrier's rights of subrogation against Lessor for any and all loss
or damage.

        In addition to the foregoing minimum insurance coverage, Lessee shall
procure and maintain such other insurance coverages as Lessor may require from
time to time during the term of this Lease. All policies shall contain a
clause requiring the insurer to furnish Lessor with at least 30 days' prior
written notice of any material change, cancellation or non-renewal of coverage.
Upon execution of this Lease, Lessee shall furnish Lessor with a certificate of
insurance or other evidence satisfactory to Lessor that such insurance
coverages are in effect, provided, however, that Lessor shall be under no duty
either to ascertain the existence of or to examine such insurance coverage or
to advise Lessee in the event such insurance coverage should not comply with
the requirements hereof. In case of failure of Lessee to procure or maintain
insurance, Lessor may at its option obtain such insurance, the cost of which
will be paid by the Lessee as additional rentals. Lessee hereby irrevocably
appoints Lessor as Lessee's attorney-in-fact to file, settle or adjust, and
receive payment of claims under any such insurance policy and to endorse
Lessee's name on any checks, drafts or other instruments in payment of such
claims. Lessee further agrees to give Lessor prompt notice of any damage to, or
loss of, the Equipment, or any part thereof.

14. LIMITATION OF LIABILITY

        Lessor shall have no liability in connection with or arising out of the
ownership, leasing, furnishing, performance or use of the Equipment or any
special, indirect, incidental or consequential damages of any character,
including, without limitation, loss of use of production facilitates or
equipment, loss of profits, property damage or lost production, whether
suffered by Lessee or any third party. 

15. FURTHER ASSURANCES

        Lessee shall promptly execute and deliver to Lessor such further
documents and take such further action as Lessor may require in order to more
effectively carry out the intent and purpose of this Lease. Lessee shall
provide to Lessor within 120 days after the close of each of Lessee's fiscal
years, and, upon Lessor's request, within 45 days of the end of each quarter of
Lessee's fiscal year, a copy of its financial statements prepared in accordance
with generally accepted accounting principles. Lessee shall execute and deliver
to Lessor upon Lessor's request such instruments and assurances as Lessor deems
necessary for the confirmation, preservation or perfection of this Lease and
Lessor's rights hereunder, including, without limitation, such corporate
resolutions and opinions of counsel as Lessor may request from time to time,
and all schedules, forms and other reports as may be required to satisfy
obligations imposed by taxing authorities. In furtherance thereof, Lessor may
file or record this Lease or a memorandum or a photocopy hereof (which for the
purposes hereof shall be effective as a financing statement) so as to give
notice to third parties, and Lessee hereby appoints Lessor as its
attorney-in-fact to execute, sign, file and record UCC financing statements and
other lien recordation documents with respect to the Equipment where Lessee
fails or refuses to do so after Lessor's written request, and Lessee agrees to
pay or reimburse Lessor for any filing, recording or stamp fees or taxes
arising from any such filings.

16. ASSIGNMENT

        This Lease and all rights of Lessor hereunder shall be assignable by
Lessor absolutely or as security, without notice to Lessee, subject to the
rights of Lessee hereunder. Any such assignment shall not relieve Lessor of its
obligations hereunder unless specifically assumed by the assignee, and Lessee
agrees it shall not assert any defense, rights of set-off or counterclaim
against any assignee to which Lessor shall have assigned its rights and
interests hereunder, nor hold or attempt to hold such assignee liable for any
of Lessor's obligations hereunder. No such assignment shall materially increase
Lessee's obligations hereunder. Lessee agrees, upon Lessor's written request,
to provide to any such assignee an acknowledgment of such assignment confirming
the terms, conditions, representations, warranties and covenants contained in
this Lease.

        LESSEE SHALL NOT ASSIGN OR DISPOSE OF ANY OF ITS RIGHTS OR OBLIGATIONS
UNDER THIS LEASE OR ENTER INTO ANY SUBLEASE WITH RESPECT TO ANY OF THE
EQUIPMENT WITHOUT THE EXPRESS PRIOR WRITTEN CONSENT OF LESSOR.

17. LESSEE'S OBLIGATIONS UNCONDITIONAL

        This Lease is a net lease and Lessee hereby agrees that it shall not be
entitled to any abatement of rents or of any other amounts payable hereunder by
Lessee and that its obligation to pay all rent and any other amounts owing
hereunder shall be absolute and unconditional under all circumstances,
including, without limitation, the following circumstances: (i) set-off,
counterclaim, recoupment, defense or other right which Lessee may have against
Lessor, any seller or manufacturer of any Equipment or anyone else for any
reason whatsoever; (ii) the existence of any liens, encumbrances or rights of
others whatsoever with respect to any Equipment, whether or not resulting from
claims against Lessor not related to the ownership of such Equipment; or (iii)
any other event or circumstances whatsoever. Each rent or other payment made by
Lessee hereunder shall be final and Lessee will not seek to recover all or any
part of such payment from Lessor for any reason whatsoever.

18. RETURN OF EQUIPMENT

        Upon the expiration or earlier termination of the Lease with respect to
each item of Equipment and provided that the Lessee has not exercised any
purchase or renewal option with respect thereto, the Lessee shall return all,
but not less than all, of the Equipment on or before the last day of the Lease
term to a location designated by Lessor within the continental United States,
maintained and in the condition required by this Lease. During any period of
time from the expiration or earlier termination of the Lease until the
Equipment is returned in accordance with the provisions hereof or paid the
applicable purchase option price if any applicable purchase option is exercised
(the "Extended Term"), Lessee agrees to pay to Lessor monthly rent on the same
day of each month of the Extended Term as during the initial term in an amount
equal to 125% of the highest monthly rental payable during the initial term.

19. ENFORCEABILITY AND GOVERNING LAW

        Any provision of th is Lease which is unenforceable in any jurisdiction
shall, as to such jurisdiction, be in effective to the extent of such
unenforceability without invalidating the remaining provisions hereof, and any
such unenforceability in any jurisdiction shall not render unenforceable such
provisions in any other jurisdiction without limiting the generality of the
foregoing, if any payment constituting interest is made hereunder and that rate
is in excess of the maximum allowed by law, then the amount of such excess
shall, at Lessor's sole option, be refunded to Lessee or applied to Lessee's
other obligations to Lessor. To the extent permitted by applicable law, Lessee
hereby waives; (a) any provisions of law which render any provision hereof
unenforceable in any respect; (b) all rights and remedies under Sections 508
through and including 522 of the Uniform Commercial Code article or division
pertaining to personal property leasing. Any waiver of the terms hereof shall
be effective only in the specific instance and for the specific purpose given.
Time is of the essence in this Lease. The captions in this Lease are for
convenience only and shall not define or limit any of the terms hereof.

        THIS LEASE SHALL IN ALL RESPECTS BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF RHODE ISLAND. LESSEE HEREBY CONSENTS
AND SUBMITS TO THE JURISDICTION OF THE COURTS OF THE STATE OF RHODE ISLAND AND
THE FEDERAL DISTRICT COURT FOR THE DISTRICT OF RHODE ISLAND FOR THE PURPOSES OF
ANY SUIT, ACTION OR OTHER PROCEEDING ARISING OUT OF ITS OBLIGATIONS HEREUNDER,
AND EXPRESSLY WAIVES ANY OBJECTIONS THAT IT MAY HAVE TO THE VENUE OF SUCH
COURTS. LESSEE HEREBY EXPRESSLY WAIVES TRIAL BY JURY IN ANY ACTION BROUGHT ON
OR WITH RESPECT TO THIS LEASE. Any action by Lessee against Lessor for any
cause of action under this Lease shall be brought within one year after any
such cause of action first occurs.



<PAGE>   5
[LOGO]
FLEET Credit Corporation                       True Lease Schedule No.  31816-01
111 Westminster Street                                                  --------
Providence, Rhode Island 02903
                                     Lessee:      T Cell Sciences, Inc.
                                                --------------------------------
                                     Address:     38 Sidney Street
                                                --------------------------------
                                                  Cambridge, MA 02139
                                                --------------------------------
                                     Telephone:   (617) 621-1400
                                                --------------------------------

     1. Lessor and Lessee have entered into a Master Equipment Lease Agreement 
dated as of August 5, 1994 including this Lease Schedule (collectively, the 
"Lease"), pursuant to which Lessor and Lessee have agreed to lease the 
equipment described in Schedule A hereto (the "Equipment").  Lessee reaffirms 
all of its representations, warranties and covenants set forth in the Lease, 
all of the terms and provisions of which are incorporated herein by reference, 
as of the date hereof and further certifies to Lessor that Lessee has selected 
the Equipment and has received and approved the purchase order, purchase 
agreement or supply contract under which the Equipment will be acquired for 
purposes of this Lease. To the extent necessary to protect Lessor's interest 
in the Equipment, Lessee hereby grants to Lessor a first priority security 
interest in the Equipment.

     2. The assumed Acquisition Cost of the Equipment is: $ 2,000,000.00 
                                                          --------------

     3. a. Term.  The Lease Term is 60 months commencing on the Lease Term 
Commencement Date as set forth in the Acceptance Certificate to this Lease 
Schedule plus any partial period between the Acceptance Date of the Equipment 
as set forth in the Acceptance Certificate and the Lease Term Commencement Date.

        b. Rental Payments.  Lessee shall pay Lessor SIXTY rental payments in 
the following amounts plus any applicable sales/use taxes, commencing on the 
Rental Payment Commencement Date set forth in the  Acceptance Certificate and 
on the same day of each month thereafter for the entire Lease Term:

        Rental Payment Nos.                     Amount of Each
                                                Rental Payment
              01-60                              $39,354.60

        In the event that the Rental Payments set forth in any Acceptance 
Certificate hereto differ from those set forth in this Section 3(b),
the Rental Payments shall be as set forth in the Acceptance Certificate.

        c. Lessee agrees to pay Lessor, in advance, the first ONLY rental 
payments.

        d. Lessor acknowledges receipt from Lessee of a payment in the amount
of $ N/A to be held by Lessor as a deposit to secure Lessee's performance under
the Lease.

     4. The Equipment will be located at the locations specified in Schedule
A hereto.

     5. Lessor will invoice Lessee for all sales, use and/or personal property 
taxes as and when due and payable in accordance with applicable law, unless 
Lessee delivers to Lessor a valid exemption certificate with respect to such 
taxes.  Delivery of such certificate shall constitute Lessee's representation 
and warranty that no such tax shall become due and payable with respect to the  
Equipment and Lessee shall indemnify and hold harmless Lessor from and against 
any and all liability or damages, including late charges and interest which 
Lessor may incur by reason of the assessment of such tax.

     6. The rental payments may change for Equipment accepted after AUGUST 15, 
1994.

     7. Lessee represents that the depreciable life of the property, for 
purposes of Section 168 of the Internal Revenue Code of 1986, is 5 years.

Dated as of August 5, 1994                  By execution hereof, the signer
            --------- ----                  certifies that he has read, 
                                            accepted and duly executed this
                                            Lease Schedule to the Master
                                            Equipment Lease Agreement on behalf
                                            of Lessee.

LESSOR: FLEET CREDIT CORPORATION            LESSEE: T CELL SCIENCES, INC.

By: /s/ Lina M. Ferruolo                    By: /s/ Alan W. Tuck 
    -----------------------------              -----------------------------

Title: AVP                                  Title: President and CEO    
       --------------------------                  --------------------------


<PAGE>   6

FLEET CREDIT CORPORATION                                                ADDENDUM
50 Kennedy Plaza
Fifth Floor
Providence, Rhode Island 02903-2305

        This Addendum is attached to and made a part of that certain Master
Equipment Lease Agreement No. 31816 dated as of August 5, 1994 by and between
the undersigned parties (the "Lease").

        The undersigned parties hereby agree to amend the Lease as follows:

        1. Section 5 is hereby amended by adding the following thereto:
           
           (h) Lessee will maintain the following financial covenants,
           determined at the end of each of Lessee's fiscal quarters
           throughout the term of the Lease:

           (i) Cash (hereinafter defined) of not less than $10,000,000.00;

           (ii) a ratio of Cash to Total Liabilities of not less than 2:1.

                For the purposes of this section, "Cash" shall be defined as the
           sum of unrestricted cash, cash equivalents and marketable securities.

                All other financial terms contained herein that are not
           specifically defined herein shall be determined in accordance with
           GAAP.

                Lessee will furnish, within 45 days of the end of each Fiscal
           Quarter and within 120 days of the end of each Fiscal Year, a
           Compliance Certificate, certified by Lessee's chief financial
           officer, as to the compliance with the above-referenced covenants.

        2. Section 8 of the Lease is hereby amended by adding the following
thereto:

           (n) Lessee shall fail to provide Cash collateral in an amount equal
           to the Stipulated Loss Value, within 10 days of a breach of the
           covenants contained in Section 5(h) hereunder.

        All capitalized terms used herein which are not defined herein shall
have the meaning given to such terms in the Lease.

        Except as specifically set forth herein, all of the terms and conditions
of the Lease remain in full force and effect and are hereby ratified and
affirmed. To the extent that the provisions of this Rider conflict with any
provisions contained in the Lease, the provisions of this Rider will control.

Dated as of: August 5, 1994

     FLEET CREDIT CORPORATION                      T CELL SCIENCES, INC.

BY: /s/ Lina M. Ferruolo                     BY: /s/ Alan W. Tuck
    -------------------------------              -------------------------------

TITLE: AVP                                   TITLE: President and CEO
       ----------------------------                 ----------------------------




<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED CONDENSED FINANCIAL STATEMENTS OF T CELL SCIENCES, INC. FOR THE SIX
MONTHS ENDED JUNE 30, 1995 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-START>                             JAN-01-1995
<PERIOD-END>                               JUN-30-1995
<CASH>                                      10,465,083
<SECURITIES>                                         0
<RECEIVABLES>                                  396,181
<ALLOWANCES>                                  (10,000)
<INVENTORY>                                    492,854
<CURRENT-ASSETS>                            11,967,985
<PP&E>                                       3,732,782
<DEPRECIATION>                             (2,970,631)
<TOTAL-ASSETS>                              14,941,106
<CURRENT-LIABILITIES>                        2,145,325
<BONDS>                                              0
<COMMON>                                        17,057
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                  12,597,151
<TOTAL-LIABILITY-AND-EQUITY>                12,614,208
<SALES>                                      1,237,483
<TOTAL-REVENUES>                             2,374,099
<CGS>                                          972,207
<TOTAL-COSTS>                                7,750,498
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           (381,065)
<INCOME-PRETAX>                            (4,995,334)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (4,995,334)
<EPS-PRIMARY>                                    (.29)
<EPS-DILUTED>                                        0
        

</TABLE>